Form 4: BioLife Solutions EVP & Chief Scientific Officer Reports Routine Stock Transactions, Including Significant Restricted Stock Grant

BioLife Solutions' EVP & Chief Scientific Officer, Aby J. Mathew, reported the sale of 521 common shares to cover tax obligations and the acquisition of 45,269 restricted stock units.

Summary

• Aby J. Mathew, EVP & Chief Scientific Officer of BioLife Solutions Inc. (BLFS), filed a Form 4 detailing recent changes in his beneficial ownership.
• On May 28, 2025, Mr. Mathew disposed of 521 shares of common stock at a price of $22.46 per share.
• This sale was executed pursuant to a Rule 10b5-1(c) trading plan adopted on February 24, 2022, specifically to satisfy tax withholding obligations related to the vesting of restricted stock.
• Following this sale, Mr. Mathew's direct beneficial ownership of common stock was 308,486 shares.
• On May 29, 2025, Mr. Mathew acquired 45,269 shares of common stock through a restricted stock grant.
• This grant was made under the BioLife Solutions 2023 Performance Incentive Plan and is scheduled to fully vest on May 29, 2029, which is the fourth anniversary of the measurement date.
• After both transactions, Mr. Mathew's direct beneficial ownership of common stock increased to 353,755 shares.

Sentiment

Score: 7

Explanation: The sentiment is moderately positive. While there was a sale of shares, it was for tax purposes and part of a pre-arranged plan. The significant grant of restricted stock units, vesting over several years, indicates a strong alignment of the executive's long-term interests with the company's future performance, which is generally viewed favorably by investors.

Positives

• The acquisition of 45,269 restricted stock units demonstrates continued equity compensation and aligns the EVP & Chief Scientific Officer's long-term interests with the company's performance.
• The restricted stock grant vests over four years, indicating a long-term commitment from the executive.

Negatives

• A sale of 521 common shares occurred, although it was explicitly for tax withholding purposes and part of a pre-arranged 10b5-1 plan.

Future Outlook

The acquisition of restricted stock units with a vesting period extending to May 29, 2029, indicates a long-term incentive structure for the EVP & Chief Scientific Officer, aligning their future compensation with the company's sustained performance.

Management Comments

• The sale reported herein was made pursuant to a Rule 10b5-1(c) trading plan adopted by the reporting person effective as of February 24, 2022, to satisfy tax withholding obligations in connection with the vesting of shares of restricted stock.
• The restricted stock was granted pursuant to the BioLife Solutions 2023 Performance Incentive Plan and fully vests on the fourth anniversary of the measurement date of May 29, 2025.

Industry Context

Form 4 filings are routine disclosures for company insiders, reporting changes in their beneficial ownership of company securities. These transactions, involving a tax-related sale and a restricted stock grant, are common occurrences in executive compensation and personal financial management within publicly traded companies.

Corporate Governance

Stakeholder Impact

• Shareholders: The grant of restricted stock to a key executive demonstrates continued management commitment and aligns executive incentives with long-term shareholder value creation.
• Employees: Reflects the company's compensation strategy, potentially influencing employee morale and retention through similar incentive structures.

Next Steps

• The restricted stock units granted on May 29, 2025, are scheduled to fully vest on May 29, 2029.

Key Dates

Recommendation

Keywords

BioLife Solutions, BLFS, Form 4, insider trading, stock transactions, restricted stock, equity compensation, Aby J. Mathew, SEC filing